Nuclear Medicine Institute

תמונה ראשית-רפואה גרעינית (איזוטופים)

Nuclear Medicine Institute

The Nuclear Medicine Institute at Rambam Health Care Campus provides the full range of nuclear medical imaging services for diagnostic purposes, and to monitor the response to various treatment strategies. The institute also provides treatment using radioactive materials for medical conditions such as thyroid, liver, and bone diseases and lymphoma.

The institute's hybrid imaging systems offer sophisticated diagnostic capabilities. For oncology patients, the institute is the single center in Northern Israel offering PET/CT studies, which enable development of accurate and focused treatment strategies; surgical approaches and radiation fields can be planned more precisely and chemotherapy can be tailored according to the patient’s imaging results.

PET/CT is also applied to new clinical indications, developed and explored in a pioneering approach at Rambam for diagnosis and assessment of infectious processes, particularly in diabetic patients. In the field of cardiology, the novel SPECT/64-slice CT device (one of few systems worldwide) can determine prognosis of patients after acute myocardial infarction, evaluate risk prior to surgery, and define medical or interventional therapeutic strategies in patients with localized or diffuse coronary artery disease.

Nuclear medicine is also successfully applied in Sports Medicine for evaluating skeletal changes and bone pain, for guiding treatment in a wide variety of endocrine diseases, in assessment of a variety of disease processes in children, and in many other clinical fields.
The PET/CT and SPECT/CT imaging technologies were developed in collaboration with physicians at Rambam's Nuclear Medicine Institute, whose expertise in the clinical use of these systems is unsurpassed.

The institute is involved in a wide range of clinical and research activities at Rambam and in collaboration with the Technion, as well as in international joint projects with institutions such as the Harvard Joint Program in Nuclear Medicine, Johns Hopkins and Vanderbilt Universities.